Targeting a

Fuller Life

Rain Oncology develops innovative, targeted therapies to help patients with cancer get their life back.

We focus on cancers where we can genetically identify patients most likely to benefit from treatment.

About Rain

milademetan clinical program

Learn more

→

View Our Pipeline

Milademetan is an oral agent that targets the MDM2*-p53 interaction, a key mediator of many malignancies. Milademetan is currently in clinical development for patients with MDM2-dependent, TP53 wildtype cancers.

Resources & Publications

MDM2 inhibition in combination with MEK inhibition in pre-clinical models of lung adenocarcinomas with MDM2 amplification

Arielle Elkrief, Igor Odintsov, Vladimir Markov, Rebecca Caeser3, Pawel Sobczuk, Sam E. Tischfield, Umesh Bhanot, Emily Cheng, Alexander Drilon, Gregory J. Riely, William W. Lockwood, Elisa de Stanchina, Vijaya G. Tirunagaru, Robert C. Doebele, Álvaro Quintanal-Villalonga, Charles M. Rudin, Romel Somwar and Marc Ladanyi

MDM2 inhibitor milademetan: Safety profile and management of adverse events

Chiara Fabbroni, Robin L. Jones, Andrea Napolitano, Tammy Linback, Elaine MacNeilly, Feng Xu, Laetitia Simeral

A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas

Mrinal M. Gounder, MD1; Todd M. Bauer, MD ; Gary K. Schwartz, MD ; Amy M. Weise, DO ; Patricia LoRusso, DO, PhD ; Prasanna Kumar, PhD ; Ben Tao, MS ; Ying Hong, PhD ; Parul Patel, MSc ; Yasong Lu, PhD ; Arnaud Lesegretain ; Vijaya G. Tirunagaru, PhD ; Feng Xu, MS ; Robert C. Doebele, MD, PhD ; and David S. Hong, MD

All Resources

Rain in the News

Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 10, 2023 4:05 PM

NEWARK, Calif., August 10, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), today reports financial results for the second quarter ended June 30, 2023, and provides a corporate update. “Rain has been aggressively pursuing a multitude of opportunities as we seek to leverage our clinical execution capabilities and strong cash position to add value to our shareholders”, said Avanish Vellanki, co-founder and chief executive officer of Rain. “Our efforts are focused on licensing or acquiring differentiated clinical-stage programs, as well as avenues to partner with companies utilizing proprietary technology that may help develop drug candidates entering the clinic. We are very excited about the progress we’ve made and recognize it’s important to act expeditiously. We will provide an update publicly on these endeavors at the appropriate time.”

Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023

July 26, 2023 8:00 AM

NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company’s business and financial results.

Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs

May 30, 2023 8:30 AM

NEWARK, Calif., May 30, 2023 – Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a clinical stage company developing precision oncology therapeutics today announced an update to its clinical strategy for milademetan, its small molecule inhibitor of the MDM2-p53 complex, to optimize Company resources. The Company is focused on reducing its cash burn with the expectation to extend cash runway to year-end 2026.

*MDM2, mouse double minute 2 homolog.